AI in Breast Imaging: New BreastCT.com Article Examines IzoView’s Competitive Edge
Rhea-AI Summary
Izotropic (OTCQB: IZOZF) has published a new article on BreastCT.com highlighting the competitive advantages of its IzoView Breast CT Imaging System in AI-integrated breast imaging. The article emphasizes IzoView's purpose-built design for artificial intelligence integration, featuring a proprietary reconstruction algorithm and compression-free scanning capability that delivers high-quality 3D images in just 10 seconds.
The system, targeted at a USD $500K price point, addresses growing demand for advanced breast screening solutions, particularly for dense breast tissue. IzoView's architecture combines exclusive AI capabilities with scalable software features, positioning it as a future-ready platform in the evolving landscape of intelligent medical imaging.
["Purpose-built design for AI integration with proprietary reconstruction algorithm", "Fast 10-second compression-free scanning capability", "Competitive USD $500K target price point", "Specifically addresses dense breast tissue screening challenges"]Positive
- None.
Negative
- None.
News Market Reaction – IZOZF
In the Sep 25 session, IZOZF gained 4.11%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.”
The article is the latest addition to BreastCT.com, Izotropic’s growing educational content platform developed to support the Company’s commercialization strategy, raise awareness of its flagship device, the IzoView Breast CT Imaging System, and define its leadership in the emerging category of AI-integrated breast imaging.
As global demand accelerates for advanced screening solutions, particularly in patients with dense breast tissue, this article highlights why legacy systems fall short and how IzoView was purpose-built for the future of intelligent imaging.
Key takeaways from the article include:
- AI Is Improving Breast Cancer Detection at Scale
Global studies and new FDA-approved tools confirm AI boosts accuracy and speeds up diagnosis, setting the stage for a new standard in imaging. - Outdated Imaging Systems Limit AI's Full Potential
Most AI tools are retrofitted onto legacy breast imaging systems that can struggle with dense breast tissue, but they can't overcome the fundamental limitations of the hardware. - IzoView Was Designed Specifically for AI-Driven Imaging
With a proprietary reconstruction algorithm, true 3D hardware, and compression-free scans, IzoView delivers ultra-high-quality images in just 10 seconds. - A Protected Platform with Built-In Advantage
IzoView combines exclusive AI capabilities, a USD$500 K target price, and scalable software features, positioning it as a future-ready platform, not just a device.
To read the full article, visit: https://breastct.com/artificial-intelligence
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
